[A transdermal patch of rivastigmine (Exelon)].
Inhibitors of acetylcholinesterase provide a modest symptomatic benefit for a majority of patients with Alzheimer's disease. Cholinergic "secondary" effects are variable, but sometimes quite invalidating. Nausea and vomiting appear to be linked to peak plasma concentration of the drug. A transdermal patch of rivastigmine is available that allows to obtain a lower peak of concentration, less gastro-intestinal side effects, and an efficacy similar to the oral capsules of rivastigmine.
Salmon
E
E
Service de Neurologie, CHU Sart Tilman, Liège, Belgique.
D000279:Administration, Cutaneous; D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D006801:Humans; D048448:Phenylcarbamates / Q000008:administration & dosage*; D000068836:Rivastigmine
D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine